Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Eli Lilly and Company
Sort By
Newest First
1 / 4
1 / 4
Acquirement
Lilly to Acquire Scorpion Therapeutics' Mutant-Selective PI3Kα Inhibitor Program
Eli Lilly and Company
PR-01-25-NI-14
Jan 14, 2025
Breakthrough Results
Breakthrough Results for Jardiance® (Empagliflozin) Confirm Emperor-preserved as First and Only Successful Trial for Heart Failure with Preserved Ejection Fraction
Eli Lilly and Company
PR-M07-21-04
Sep 05, 2024
M&A
Lilly Announces Acquisition of Protomer Technologies
Eli Lilly and Company
PR-M07-21-06
Jul 15, 2021
Phase III
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Eli Lilly and Company
PR-M04-21-028-1017
Apr 26, 2021
COVID-19
Lilly Modified COVID-19 Purchase Agreement for Bamlanivimab and Etesevimab Together
Eli Lilly and Company
PR-M04-21-010
Apr 13, 2021
FDA Authorization
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19
Eli Lilly and Company
PR-M11-20-022
Nov 25, 2020
COVID-19
Lilly Announces Agreement with U.S. Government to Supply 300,000 Vials of Investigational Neutralizing Antibody to Fight COVID-19
Eli Lilly and Company
PR-M10-20-18-1207
Oct 28, 2020
Lilly Statement on the NIAID Decision to Pause Enrollment in ACTIV-3 Clinical Trial
Eli Lilly and Company
PR-M10-20-09
Oct 15, 2020
Oncology
Eli Lilly Drug Significantly Reduces the Risk of Breast Cancer Returning
Eli Lilly and Company
PR-M06-20-NI-020
Jun 16, 2020
COVID-19 Clinical Testing
Lilly Begins Clinical Testing of Therapies for COVID-19
Nice Insight
PR-M04-20-NI-018
Apr 13, 2020
New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.
Eli Lilly and Company
PR-M04-20-NI-010-1621
Apr 07, 2020
Medical Professionals Across Merck, Pfizer, and Eli Lilly Volunteer Amid COVID-19 Pandemic
Eli Lilly and Company
PR-M04-20-NI-004
Apr 02, 2020
Coronavirus
Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines
Eli Lilly and Company
PR-M03-20-NI-020
Mar 12, 2020
Partnership
Eli Lilly and Company to Partner in Support of the Olympic and Paralympic Games Tokyo 2020
Eli Lilly and Company
PR-M02-20-NI-030
Feb 21, 2020
Investment
Governor Cooper Announces Over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant
Eli Lilly and Company
PR-M01-20-NI-034
Jan 23, 2020
M&A
Lilly Announces Agreement to Acquire Dermira
Eli Lilly and Company
PR-M01-20-NI-032
Jan 21, 2020
Drug Pricing
Lilly Expands Insulin Affordability Options
Eli Lilly and Company
PR-M01-20-NI-028
Jan 17, 2020
Investment
Lilly Announces $400 Million Capital Investment in Manufacturing Facilities in Indianapolis
Eli Lilly and Company
PR-M11-19-NI-028
Nov 20, 2019
Phase III
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib for Moderate to Severe Atopic Dermatitis
Eli Lilly and Company
PR-M09-19-NI-001
Sep 03, 2019
Licensing Agreement
Innovent Enters a Licensing Agreement with Lilly to Develop & Commercialize a Novel Diabetes Medicine in China
Innovent
PR-M08-19-NI-076
Aug 27, 2019
